Kumaraguru Raja
Stock Analyst at Brookline Capital
(0)
# 4830
Out of 5,225 analysts
19
Total ratings
18.18%
Success rate
-29.69%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
QNCX Quince Therapeutics | Initiates Coverage On: Buy | 9 | 1.11 | 710.81% | 1 | Dec 18, 2024 | |
PALI Palisade Bio | Initiates Coverage On: Buy | 38 | 0.74 | 5035.14% | 1 | Nov 20, 2024 | |
SABS SAB Biotherapeutics | Initiates Coverage On: Buy | 8 | 1.44 | 455.56% | 1 | Jun 7, 2024 | |
FBRX Forte Biosciences | Initiates Coverage On: Buy | 100 | 6.78 | 1374.93% | 2 | May 30, 2024 | |
HEPA Hepion Pharmaceutica... | Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 150 | 0.7 | 21328.57% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 15 | 3.93 | 281.68% | 1 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 9 | n/a | n/a | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 21 | 2.89 | 626.64% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 15 | n/a | n/a | 1 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Buy | 90 | 44 | 104.55% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 29 31 | 0.55 | 5536.36% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 3360 | 0.76 | 442005.26% | 1 | Sep 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 320 | n/a | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 120 | n/a | n/a | 1 | Mar 25, 2021 |